# A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer

> **NCT04674956** · PHASE3 · UNKNOWN · sponsor: **RenJi Hospital** · enrollment: 401 (estimated)

## Conditions studied

- Pancreatic Cancer Stage IV
- Pancreatic Cancer Metastatic

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Paclitaxel(Albumin Bound) and Gemcitabine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04674956
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-04
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 401 (ESTIMATED)
- **Last updated:** 2024-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04674956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04674956, "A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04674956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*